ClinicalTrials.gg
CompletedNCT03318393Updated Jan 31, 2023Results posted

Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO

A Phase 4 interventional study of Bivalirudin and Unfractionated heparin in Extracorporeal Membrane Oxygenation Complication, Pediatric ALL and Anticoagulants, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 169 open to participants now, 275 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Enrollment
689th of 1,269
30 · median 35
Started
2018
with 38 others
Phase 4
10 of 1,545
1 open now
Registered
1,177th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 689th largest by enrollment of the 1,269 interventional ones that give a count, is one of 39 that started in 2018, is one of 10 in phase 4, and was the 1,177th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 472 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

169 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

164 more — sign in →

All 169 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 95 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The investigators will prospectively enroll 30 neonatal and pediatric ECMO patients at a single pediatric Level 1 trauma center. The patients will be randomized into two arms; one arm will receive unfractionated heparin and the other arm will receive bivalirudin. There will be 15 patients in each arm for a total of 30 patients.

Primary aim will be to compare the efficacy of bivalirudin to unfractionated heparin.

Read the detailed description

The investigators will prospectively enroll 30 neonatal and pediatric ECMO patients at a single pediatric Level 1 trauma center. The patients will be randomized into two arms; one arm will receive unfractionated heparin and the other arm will receive bivalirudin. There will be 15 patients in each arm for a total of 30 patients.

The investigators hypothesize that neonatal and pediatric ECMO patients receiving bivalirudin will spend more time at goal anticoagulation and will experience less hemorrhagic and thrombotic complications when compared to patients receiving unfractionated heparin. Primary aim will be to compare the efficacy of bivalirudin to unfractionated heparin. The investigators secondary aim will be to define the incidence of hemorrhagic and thrombotic complications in patients receiving bivalirudin during ECMO.

03

Conditions studied

  • Extracorporeal Membrane Oxygenation Complication
  • Pediatric ALL
  • Anticoagulants
04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1 day to less than 18 years
  • Cared for in the pediatric intensive care unit or pediatric cardiac intensive care unit
  • receiving venovenous or venoarterial ECMO

Exclusion criteria

Exclusion Criteria:

  • Patients with known or suspected heparin induced thrombocytopenia prior to consent
  • Patients with hepatic failure defined as coagulopathy with elevated transaminases more than three times normal values
  • Patients with plan to decannulate from ECMO within 48 hours
  • Known or suspected pregnant women
  • Previous enrollment in this study
  • Primary language spoken that is not English or Spanish
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Unfractionated heparin group

    Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.

    Drug: Unfractionated heparin

  • Experimental
    Bivalirudin group

    Patients randomized to this arm will receive anticoagulation with bivalirudin

    Drug: Bivalirudin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Time Spent at Goal Anticoagulation

    Time frame: through study completion, an average of 1-2 weeks

Secondary outcomes

  1. Number of Participants With One or More Major Bleeding Events

    Bleeding events will include drop in hemoglobin, surgical site bleeding, intracranial hemorrhage, fatal bleeding, extra surgical or unexpected surgical site bleeding

    Time frame: through study completion, an average of 1-2 weeks

Other outcomes

  1. Number of Blood Products Transfused

    Will include fresh frozen plasma (FFP), packed red blood cells (pRBCs), platelets and cryoprecipitate

    Time frame: through study completion, an average of 1-2 weeks

07

Results

Posted Jan 31, 2023

Participant flow

Participant flow — Overall Study
MilestoneUnfractionated Heparin GroupBivalirudin Group
Started1416
Completed1416
Not completed00

Outcome measures

PrimaryPercentage of Time Spent at Goal Anticoagulation
Time frame:
through study completion, an average of 1-2 weeks
Reported as:
Median · percentage of time
Percentage of Time Spent at Goal Anticoagulation
percentage of timeUnfractionated Heparin GroupBivalirudin Group
Percentage of Time Spent at Goal Anticoagulation0.63 (0.5 to 0.82)0.49 (0.31 to 0.54)
SecondaryNumber of Participants With One or More Major Bleeding Events

Bleeding events will include drop in hemoglobin, surgical site bleeding, intracranial hemorrhage, fatal bleeding, extra surgical or unexpected surgical site bleeding

Time frame:
through study completion, an average of 1-2 weeks
Reported as:
Number · participants
Number of Participants With One or More Major Bleeding Events
participantsUnfractionated Heparin GroupBivalirudin Group
Number of Participants With One or More Major Bleeding Events77
Other pre-specifiedNumber of Blood Products Transfused

Will include fresh frozen plasma (FFP), packed red blood cells (pRBCs), platelets and cryoprecipitate

Time frame:
through study completion, an average of 1-2 weeks
Reported as:
Median · mls/kg/day
Number of Blood Products Transfused
mls/kg/dayUnfractionated Heparin GroupBivalirudin Group
pRBCs12.2 (5.52 to 14.46)6.29 (2.49 to 8.41)
Platelets13.58 (2.43 to 23.94)4.55 (0.55 to 11.51)
FFP0.16 (0 to 2.84)1.15 (0.24 to 2.79)
Cryoprecipitate0 (0 to 0.19)0.1 (0 to 1.14)

Adverse events

Collected over From Baseline, daily until the end of study, an average of up to 0.1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Unfractionated Heparin Group2/14 (14.3%)7/14 (50%)0/14 (0%)
Bivalirudin Group3/16 (18.8%)7/16 (43.8%)0/16 (0%)
Most frequent serious events
Most frequent serious events
EventUnfractionated Heparin GroupBivalirudin Group
Major bleeding eventBlood and lymphatic system disorders7/147/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Unfractionated Heparin GroupBivalirudin GroupTotal
<=18 years141630
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Unfractionated Heparin GroupBivalirudin GroupTotal
Female71118
Male7512
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Unfractionated Heparin GroupBivalirudin GroupTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Unfractionated Heparin GroupBivalirudin GroupTotal
United States141630
08

Study locations

1 site
  • Children's Medical Center
    Dallas, Texas 75235, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Oct 2021, 42 months.

Results were first posted in Jan 2023, 1 year 3 months after primary completion.

Of 30 phase 4 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 123. This study's 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2017
First posted
Oct 23, 2017
StartActual
Mar 25, 2018
Primary completionActual
Oct 8, 2021
CompletionActual
Oct 8, 2021
Results first posted
Jan 31, 2023
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03318393
Responsible party
Lakshmi Raman (PROFESSOR, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Oct 23, 2017
Start date
Mar 25, 2018
Primary completion
Oct 8, 2021
Completion
Oct 8, 2021
Results posted
Jan 31, 2023
Last update
Jan 31, 2023

Study contacts

Ali McMichael, MD
principal investigator · UT Southwestern

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bivalirudin

Start the discussion